NLS Pharmaceutics AG has announced an amendment to their Securities Purchase Agreement, originally dated March 27, 2025. The amendment involves a subsequent closing where the company is required to issue 606,061 Preferred Shares. However, at present, only 37,783 Preferred Shares and 591,532 preferred participation certificates are authorized for issuance. This update is part of the company's ongoing efforts to manage its securities transactions and has been disclosed in a recent filing with the Securities and Exchange Commission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.